South Africa court bars compounded Ozempic, bolstering Novo's IP defense amid US pricing battle

What happened

Novo Nordisk secured an interim interdict from South Africa's High Court barring local pharmacy group iDexis from manufacturing and selling compounded weight-loss medicines containing semaglutide, signaling tightening regulatory scrutiny of unregistered copycats. The ruling reinforces Novo's IP moat, yet the core investment debate remains centered on US gross-to-net compression and the oral share battle against Lilly's newly approved Foundayo. With the stock trading at 10.3x P/E and $43.9, the market already prices in significant headwinds, making this legal win a modest positive that does not alter the fundamental volume-versus-price equation. Novo’s Q1 2026 results showed 85.9% gross margins and DKK 12.8B free cash flow, supporting capacity expansion and a DKK 15B buyback, but the 6–12 month payoff hinges on observable script growth from Wegovy Pill, HD 7.2mg, and the mid-2026 Medicare Part D obesity pilot. Investors should treat this ruling as a supportive tailwind for the branded franchise, but the thesis depends on whether volume levers can offset persistent net price declines and stabilize oral share against Lilly.

Implication

If Novo can demonstrate sustained oral volume growth and stable share through Q4 2026, the current 10.3x P/E offers asymmetric upside. Failure to stabilize net price or oral share justifies a lower valuation, even with strong cash flow and IP protection.

Thesis delta

The South Africa interdict modestly strengthens the IP moat narrative by curbing compounded competition, but it does not alter the core thesis that US net price compression and oral share competition are the dominant drivers. The focus remains on weekly prescription data and oral share versus Foundayo, with the ruling providing a marginal positive but no change to the base case.